ReviewFrontiers in oncology2020
Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ambulatory models for autologous stem-cell transplantation: a systematic review of the health impact.Frontiers in immunology · 2024Pooled it
- Patient preferences for treatment‑free intervals in multiple myeloma: mixed‑methods insights on monitoring trade‑offs and supportive care improvements.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Supportive care needs and supply matching questionnaire for family caregivers of patients with multiple myeloma: development and cross-sectional validation study.BMC nursing · 2026Article
- Predicting adverse events for risk stratification of chemotherapy based stem cell mobilization in multiple myeloma.NPJ digital medicine · 2026Article
- Health-related quality of life after autologous stem cell transplantation for multiple myeloma or lymphoma impacts professional activity- an analysis from two German tertiary care centers.Frontiers in oncology · 2026Article
- Contextual analysis of hematopoietic stem cell transplantation in outpatients.Revista brasileira de enfermagem · 2026Article
- Intra-apheresis Cycling to Improve the Clinical Efficacy of Peripheral Blood Stem Cell Donations.Sports medicine (Auckland, N.Z.) · 2025Review
- [Chinese expert consensus on standard procedures for the outpatient management of patients with multiple myeloma (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Article
- [Retrospective clinical study on cryopreservation-free integrated autologous hematopoietic stem cell transplantation model for newly diagnosed multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Policy and perspective on outpatient programs for autologous hematopoietic cell transplantation and immune-effector cell therapy administration.Frontiers in immunology · 2024Review
- Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.Annals of hematology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is the most common indication for autologous stem cell transplantation (ASCT), and outpatient models have been widely developed in this setting. Although numerous studies have demonstrated the safety and feasibility of outpatient ASCT, it is not a routine procedure. Stringent guidelines for patient selection and clinical management, including functional status, caregiver support, and psychological aspects, are essential to identify eligible patients. However, there is still no general agreement on these criteria. Quality of life data are limited and contradictory. There is considerable variability in outpatient transplant models, and there are no randomised studies supporting the use of one over the other. Studies evaluating results in terms of long-term survival, transplant toxicity in comparison with a standard approach are lacking. The procedure is cost-effective within the context of a hospital budget, but an in-depth analysis of the real cost of these programmes has yet to be performed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.